Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test.
Minso R, Schulz A, Dopfer C, Alfeis N, Barneveld AV, Makartian-Gyulumyan L, Hansen G, Junge S, Müller C, Ringshausen FCC, Sauer-Heilborn A, Stanke F, Stolpe C, Tamm S, Welte T, Dittrich AM, Tümmler B. Minso R, et al. Among authors: junge s. BMJ Open Respir Res. 2020 Oct;7(1):e000736. doi: 10.1136/bmjresp-2020-000736. BMJ Open Respir Res. 2020. PMID: 33020115 Free PMC article.
Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy.
Stanke F, Pallenberg ST, Tamm S, Hedtfeld S, Eichhorn EM, Minso R, Hansen G, Welte T, Sauer-Heilborn A, Ringshausen FC, Junge S, Tümmler B, Dittrich AM. Stanke F, et al. Among authors: junge s. Front Pharmacol. 2023 Jan 27;14:1114584. doi: 10.3389/fphar.2023.1114584. eCollection 2023. Front Pharmacol. 2023. PMID: 36778025 Free PMC article.
Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity.
Schütz K, Pallenberg ST, Kontsendorn J, DeLuca D, Sukdolak C, Minso R, Büttner T, Wetzke M, Dopfer C, Sauer-Heilborn A, Ringshausen FC, Junge S, Tümmler B, Hansen G, Dittrich AM. Schütz K, et al. Among authors: junge s. Front Pharmacol. 2023 Jul 4;14:1171544. doi: 10.3389/fphar.2023.1171544. eCollection 2023. Front Pharmacol. 2023. PMID: 37469865 Free PMC article.
High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study.
Scheuing N, Holl RW, Dockter G, Hermann JM, Junge S, Koerner-Rettberg C, Naehrlich L, Smaczny C, Staab D, Thalhammer G, van Koningsbruggen-Rietschel S, Ballmann M. Scheuing N, et al. Among authors: junge s. PLoS One. 2014 Nov 13;9(11):e112578. doi: 10.1371/journal.pone.0112578. eCollection 2014. PLoS One. 2014. PMID: 25393021 Free PMC article.
Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus.
Junge S, Görlich D, den Reijer M, Wiedemann B, Tümmler B, Ellemunter H, Dübbers A, Küster P, Ballmann M, Koerner-Rettberg C, Große-Onnebrink J, Heuer E, Sextro W, Mainz JG, Hammermann J, Riethmüller J, Graepler-Mainka U, Staab D, Wollschläger B, Szczepanski R, Schuster A, Tegtmeyer FK, Sutharsan S, Wald A, Nofer JR, van Wamel W, Becker K, Peters G, Kahl BC. Junge S, et al. PLoS One. 2016 Nov 18;11(11):e0166220. doi: 10.1371/journal.pone.0166220. eCollection 2016. PLoS One. 2016. PMID: 27861524 Free PMC article.
Effects of a Partially Supervised Conditioning Program in Cystic Fibrosis: An International Multicenter, Randomized Controlled Trial (ACTIVATE-CF).
Hebestreit H, Kriemler S, Schindler C, Stein L, Karila C, Urquhart DS, Orenstein DM, Lands LC, Schaeff J, Eber E, Radtke T; ACTIVATE-CF Study Working Group. Hebestreit H, et al. Am J Respir Crit Care Med. 2022 Feb 1;205(3):330-339. doi: 10.1164/rccm.202106-1419OC. Am J Respir Crit Care Med. 2022. PMID: 34735776 Free PMC article. Clinical Trial.
61 results